ProShare Advisors
ABCL icon

ProShare Advisors’s AbCellera Biologics ABCL Stock Holding History

ProShare Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.3K Buy
13,562
+322
+2% +$1.16K ﹤0.01% 1794
2025
Q4 		$45.3K Buy
13,240
+2,594
+24% +$11.6K ﹤0.01% 1966
2025
Q3 		$53.5K Sell
10,646
-500
-4% -$2.2K ﹤0.01% 1927
2025
Q2 		$38.2K Sell
11,146
-2,297
-17% -$5.72K ﹤0.01% 2024
2025
Q1 		$30K Sell
13,443
-547
-4% -$1.57K ﹤0.01% 2002
2024
Q4 		$41K Sell
13,990
-3,422
-20% -$9.53K ﹤0.01% 2204
2024
Q3 		$45.3K Sell
17,412
-740
-4% -$2.05K ﹤0.01% 1987
2024
Q2 		$53.7K Sell
18,152
-2,366
-12% -$8.95K ﹤0.01% 1742
2024
Q1 		$92.9K Buy
20,518
+1,978
+11% +$10.1K ﹤0.01% 1834
2023
Q4 		$106K Sell
18,540
-376
-2% -$1.74K ﹤0.01% 1774
2023
Q3 		$87K Buy
18,916
+234
+1% +$1.42K ﹤0.01% 1656
2023
Q2 		$121K Sell
18,682
-25,638
-58% -$175K ﹤0.01% 1666
2023
Q1 		$334K Sell
44,320
-5,989
-12% -$54.4K ﹤0.01% 1146
2022
Q4 		$510K Buy
50,309
+3,495
+7% +$40.4K ﹤0.01% 953
2022
Q3 		$463K Buy
46,814
+1,391
+3% +$15.3K ﹤0.01% 927
2022
Q2 		$484K Buy
45,423
+15,940
+54% +$135K ﹤0.01% 948
2022
Q1 		$287K Sell
29,483
-10,170
-26% -$96.3K ﹤0.01% 1654
2021
Q4 		$567K Buy
+39,653
New +$602K ﹤0.01% 1358

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ProShare Advisors's ABCL Position: Q1 2026 in Review

ProShare Advisors increased its AbCellera Biologics (ABCL) stake by 2.4% in Q1 2026, buying an estimated $1.16K and bringing the position to 13,562 shares worth $47.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1794.

ProShare Advisors first reported a position in ABCL in Q4 2021 and has held it in 18 quarters since. The position peaked at $567K in Q4 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • ProShare Advisors held 13,562 shares of AbCellera Biologics worth $47.3K as of Q1 2026.
  • ProShare Advisors bought 322 AbCellera Biologics shares in Q1 2026, an estimated $1.16K.
  • AbCellera Biologics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1794 holding.
  • ProShare Advisors first reported a position in AbCellera Biologics in Q4 2021 and has held it in 18 quarters since.
  • ProShare Advisors's AbCellera Biologics position peaked at $567K in Q4 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.